Atypical Hemolytic Uremic Syndrome
📧 Sign up to get email alerts when something new happens for Atypical Hemolytic Uremic Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) [Phase 3]
This update reports on a Phase 3 study evaluating crovalimab for atypical hemolytic uremic syndrome in adults and adolescents, covering effi…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS [Phase 4]
Phase 4 post-marketing clinical trial evaluating ravulizumab in patients with atypical Hemolytic Uremic Syndrome (aHUS) is currently recruit…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
This clinical trial update indicates that a study evaluating the safety of Ravulizumab (Ultomiris) in pregnant and postpartum individuals is…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt
This is a multicenter, observational, retrospective cohort study in Egypt describing the burden and clinical characteristics of patients wit…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy [Phase 2]
A Phase 2 clinical trial evaluating NM8074 in patients with atypical hemolytic uremic syndrome is not yet recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS) [Phase 3]
Phase 3 trial update describes switching study participants with atypical hemolytic uremic syndrome from anti-C5 antibody therapy to iptacop…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy [Phase 3]
A Phase 3 trial evaluating iptacopan (LNP023) in adults with atypical hemolytic uremic syndrome who are naive to complement inhibitors; the …
-
CLINICAL_TRIALS other · 2026-03-27Clinical Trial Update: A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) [Phase 3]
Phase 3 trial evaluating crovalimab for pediatric atypical hemolytic uremic syndrome; status is active but not recruiting.
-
FDA approval · 2026-03-26FDA Approved: BKEMV — Supplemental Application (Amgen Inc)
FDA approved a supplemental application for BKEMV (eculizumab-aeeB) from Amgen.
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: New Analytic Tools for aHUS and C3G Diagnosis [NA]
An active-not-recruiting trial from Mario Negri Institute is evaluating new analytic tools to improve the diagnosis of atypical hemolytic ur…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases [NA]
This clinical trial update describes a project to develop RNA-Seq as a complementary diagnostic tool for rare diseases, with recruitment ong…
-
CLINICAL_TRIALS trial_result · 2026-02-10Clinical Trial Update: Ravulizumab Outcomes in Polish Patients With aHUS
A clinical trial evaluating ravulizumab outcomes in Polish patients with atypical hemolytic uremic syndrome is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients
An observational, non-interventional study aimed at describing how Atypical Hemolytic Uremic Syndrome presents, how it is treated in real-wo…
-
CLINICAL_TRIALS trial_result · 2025-12-10Clinical Trial Update: Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome [Phase 3]
A Phase 3 safety and efficacy trial of OMS721 in patients with atypical hemolytic uremic syndrome has been terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2025-12-08Clinical Trial Update: Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China [Phase 3]
Phase 3 trial of eculizumab in pediatric and adult participants with atypical hemolytic uremic syndrome in China has completed and results w…
-
FDA approval · 2025-11-24FDA Approved: BKEMV — Supplemental Application (Amgen Inc)
The FDA approved a supplemental application for BKEMV (eculizumab-aeeB) from Amgen, a biosimilar to eculizumab.
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium
This entry notes that a prospective study evaluating the role of complement-related thrombotic microangiopathy on the endothelium is current…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy [NA]
This clinical trial explores how rare gene mutations influence atypical hemolytic uremic syndrome and aims to inform personalized treatment …
-
CLINICAL_TRIALS research · 2025-09-16Clinical Trial Update: Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
An update on an ongoing aHUS clinical trial registry sponsored by Alexion Pharmaceuticals, currently recruiting participants.
-
FDA approval · 2025-09-02FDA Approved: EPYSQLI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approves a supplemental application for EPYSQLI (eculizumab-aagh) from Teva Pharmaceuticals USA, Inc.
-
CLINICAL_TRIALS research · 2025-07-16Clinical Trial Update: Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS [Phase 3]
Phase 3 clinical trial update evaluating long-term safety, tolerability, and efficacy of iptacopan in participants with atypical hemolytic u…
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU) [Phase 3]
A Phase 3 trial evaluating personalized spacing of eculizumab infusions guided by therapeutic pharmacological monitoring in atypical hemolyt…
-
FDA approval · 2025-03-12FDA Approved: EPYSQLI — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approves Teva's supplemental application for EPYSQLI (eculizumab-aagh), a biosimilar to eculizumab.
-
FDA approval · 2025-01-30FDA Approved: BKEMV — Supplemental Application (Amgen Inc)
FDA approved BKEMV (eculizumab-aeeb) under Amgen’s supplemental application, making a biosimilar to eculizumab available. The product is int…
-
CLINICAL_TRIALS trial_result · 2025-01-27Clinical Trial Update: A Retrospective Study to Evaluate the Clinical Outcome According to Treatment in aHUS Patients in South Korea
A retrospective study from South Korea evaluates clinical outcomes in atypical hemolytic uremic syndrome patients according to the treatment…